DCM
TPTX

Dupont Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Dupont Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,054
Closed -$241K – 1930
2021
Q4 		$241K Sell
5,054
-2,016
-29% -$90.1K 0.01% 1068
2021
Q3 		$470K Sell
7,070
-1,000
-12% -$71.2K 0.01% 920
2021
Q2 		$630K Buy
+8,070
New +$596K 0.01% 861

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Dupont Capital Management's TPTX Position: Q1 2022 in Review

Dupont Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 5,054 shares — an estimated $241K sold.

Dupont Capital Management first reported a position in TPTX in Q2 2021 and held it in 3 quarters. The position peaked at $630K in Q2 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Dupont Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Dupont Capital Management sold 5,054 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $241K.
  • Dupont Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Dupont Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $630K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.